NEW:
PARTNERING OPPORTUNITY: A humanized mAb that inhibits the blood platelet glycoprotein Ib as an effective and safe antithrombotic
SERVICE available for measurement of trough levels of either Infliximab or Adalimumab and measurement of anti-drug-antibodies towards Infliximab or Adalimumab. See http://web.me.com/qef/tl-ada/TL-ADA.html
e-News october 2010
ABOUT US
PharmAbs is a K.U.Leuven research center that focuses on antibody research, development and production. PharmAbs brings together critical mass in antibody research, a unique combination of competence and know-how and an impressive and state-of-the-art infrastructure. PharmAbs has created a unique, state-of-the-art antibody technology platform open for co-development projects with academic research groups, as well as for research collaborations with biotech companies. PharmAbs has its own dedicated research team and has operational facilities inside the founding K.U.Leuven R&D groups.
MISSION
PharmAbs focuses on the discovery and development of antibody-based products in collaboration with academic research groups or small companies. PharmAbs aims at generating tailor-made monoclonal antibodies against targets identified by academic research groups and biotech companies and on initiation of non-clinical biopharmaceutical/diagnostic development in order to generate added value for the project and bring it to a stage at which it can be adopted by an industrial partner. PharmAbs will also use its platform for the internal development of therapeutic antibodies.
In addition, fee-for-service tailor-made polyclonal and monclonal antibody production services are available for customers who need antibodies for research purposes and for biotech companies who want to outsource part of their monoclonal antibody generation and selection process. |
